… We reviewed 22 patients with NSCLC who received anlotinib combined with PD-1 mAb …
analyzed the efficacy and safety of this combination therapy by RESIST 1.1 and CTCAE 5.0. …

… anlotinib for > 12 months. The study aims included exploring the safety and efficacy of the
long-term use of anlotinib … predict the long-term efficacy of anlotinib. Additionally, we sought to …

… our study indicated that anlotinib seemed to be safe for later-… to confirm the efficacy and
safety of anlotinib as a standard … may influence the actual efficacy and safety of anlotinib. Third, …

Objective To evaluate the efficacy and safety of anlotinib-based treatment in metastatic
breast cancer (MBC) patients with failure of standard treatment. Methods We collected the …

… efficacy and safety of anlotinib in ES-SCLC. Methods: Pathologically confirmed ES-SCLC
patients receiving anlotinib … real-world efficacy and safety of anlotinib in patients with ES-SCLC. …

… In conclusion, the combination of sintilimab plus anlotinib has exhibited encouraging efficacy
and acceptable safety in this study, making it a promising option for second-line and later …

… actual clinical efficacy of … efficacy of anlotinib + ICIs are scarce now. Thus, using real
medical cases, we conducted a retrospective study to examine the efficacy and safety of anlotinib …

… The toxicity profile was generally consistent with the prior experience of anlotinib in phase
I study and the safety data of other multi-kinase inhibitors belonging to the same class (31). …

… We aimed to assess the efficacy and safety of anlotinib in … intended to explore the efficacy
and safety of anlotinib alone or together … the use of anlotinib in the treatment of these patients. …

… Anlotinib is a new multi-target tyrosine kinase inhibitor. The goal of this study is to evaluate
the efficacy and safety of anlotinib … study on the efficacy and safety of the anlotinib as multi-…